Trials / Withdrawn
WithdrawnNCT01870284
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active AS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | Adalimumab | Administered SC |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-04-01
- Completion
- 2018-04-01
- First posted
- 2013-06-06
- Last updated
- 2014-09-16
Locations
125 sites across 15 countries: United States, Argentina, Belgium, Canada, Czechia, France, Germany, Hungary, Mexico, Netherlands, Poland, Russia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01870284. Inclusion in this directory is not an endorsement.